Foundation Medicine Acquires Lexent Bio, Inc.

Eli Lilly and Company to Acquire Ventyx Biosciences

January 8, 2026

Pharmaceuticals

Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.

Agilent Technologies Acquires Avida Biomed

January 4, 2023

Biotechnology

Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.

Alexion, AstraZeneca Rare Disease Acquires LogicBio Therapeutics

November 16, 2022

Biotechnology

Alexion, AstraZeneca Rare Disease completed its acquisition of LogicBio Therapeutics, a Lexington, Massachusetts-based genomic medicine company. The deal was implemented through a cash tender offer and a merger of an Alexion subsidiary with LogicBio, with LogicBio becoming a wholly owned subsidiary of Alexion.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Blueprint Medicines Acquires Lengo Therapeutics

November 29, 2021

Biotechnology

Blueprint Medicines has entered a definitive agreement to acquire privately held precision oncology company Lengo Therapeutics for $250 million in cash plus up to $215 million in regulatory- and sales-based milestones. The deal adds Lengo’s lead oral EGFR exon 20 insertion candidate LNG-451 and other preclinical precision oncology programs to Blueprint’s lung cancer portfolio, expanding its capability in brain-penetrant EGFR inhibitors.

Sonde Health Acquires NeuroLex Laboratories

August 25, 2020

Healthcare Services

Sonde Health has acquired NeuroLex Laboratories, bringing NeuroLex's web-based voice survey platform, SurveyLex, and its biobank into Sonde's vocal biomarker technology suite. The deal combines NeuroLex's dataset and web capabilities with Sonde's mobile and voice-assistant platforms to expand research, data assets, and cross-platform voice-enabled health detection and monitoring.